Sign In
Buy NXP
$14.21
-0.0700 (-0.490%)
At Close: Aug 10, 2026
This Wall Street Pro Makes a Compelling Argument for 70% Gains on NXP Semiconductors Which Cratered Last Month
07:36am, Tuesday, 11'th Aug 2026
NXP Semiconductors (NASDAQ:NXPI | NXPI Price Prediction) currently trades at $233.43, while Cantor Fitzgerald's Street-high price target of $400 sits roughly 71% above that mark, one of the widest ana
Why NXP Semiconductors Stock Dropped 18.5% in July
05:00pm, Monday, 10'th Aug 2026
NXP beat Q2 revenue and earnings estimates on July 28, then fell 7.0% the next day. July's decline erased April's 25.6% single-day gain, leaving NXP's stock behind the S&P 500 over 12 months.
NXP Trimension Ultra-Wideband Powers BMW Group's Digital Key Plus and Presence Detection
03:00am, Tuesday, 04'th Aug 2026
NXP's Trimension Ultra-Wideband (UWB) ranging and radar solutions will be deployed by the BMW Group across its fleet, starting with selected 2026 vehicle programs NXP's Trimension NCJ29D6 family allow
NXP downgraded by UBS as China and AI risks cloud growth
10:47am, Monday, 03'rd Aug 2026
NXP Semiconductor NV (NASDAQ:NXPI) was downgraded by UBS as the investment bank warned that a potential automotive inventory correction in China and limited exposure to artificial intelligence data c
NXP in talks to buy chip developer Ambarella, FT reports
01:06pm, Friday, 31'st Jul 2026
NXP Semiconductors is in talks to buy chip designer Ambarella , the Financial Times reported on Friday, citing people familiar with the matter.
NXP Semiconductors Q2 Earnings Beat Estimates, Revenues Rise Y/Y
01:01pm, Wednesday, 29'th Jul 2026
NXPI posts Q2 earnings and revenue beats as automotive, industrial and AI data center demand lift growth, with strong Q3 guidance adding momentum.
NXP Semiconductor: A Solid Q2, And Improved Q3 Guidance Reiterates The Bull Case
09:16am, Wednesday, 29'th Jul 2026
NXP Semiconductor (NXPI) which is up by 20% YTD, but still underperformed other semiconductor stocks by a large margin, reported Q2 results on the 28th of July post market hours. Q2 results beat on bo
NXP Semiconductors Q2 Earnings Call Highlights
06:07pm, Tuesday, 28'th Jul 2026
NXP Semiconductors NASDAQ: NXPI reported second-quarter 2026 revenue and earnings above the midpoint of its guidance, citing broad-based growth across end markets and continued momentum in software-de
NXP Semiconductors Shares Slip Despite Q2 Earnings Beat
05:23pm, Tuesday, 28'th Jul 2026
NXP Semiconductors NV (NASDAQ:NXPI) posted its second-quarter results after Tuesday's closing bell, beating the Street's estimates but not impressing investors.
NXP Semiconductors Second-Quarter Profit, Revenue Climb on Growth Across End Markets
04:59pm, Tuesday, 28'th Jul 2026
The Dutch chip maker posted a profit of $767 million, driven by growth across all end markets and all regions, with particular strength among software-defined vehicle and physical AI customers.
NXP Semiconductors Reports Second Quarter 2026 Results
04:10pm, Tuesday, 28'th Jul 2026
EINDHOVEN, The Netherlands, July 28, 2026 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI) today reported financial results for the second quarter, which ended June 28, 2026. “NXP delivere
For Energy Investors, Is a Traditional Energy ETF a Better Bet Than Clean Energy?
12:30pm, Saturday, 25'th Jul 2026
State Street's fossil fuel fund delivered 41% returns over one year with far lower volatility, while iShares' renewable basket posted 33% gains but carries five times higher fees.
First global approval of a once-daily, orally administered, Complement Factor B inhibitor Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program i
Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of inn
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
10:40am, Tuesday, 14'th Jul 2026
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharma
